These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33721913)

  • 1. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
    Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
    Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
    Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
    Liu Z; Chen Z; Wang J; Zhang M; Li Z; Wang S; Dong B; Zhang C; Gao J; Shen L
    J Hematol Oncol; 2018 Aug; 11(1):109. PubMed ID: 30157900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
    Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
    Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
    Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
    Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.
    Wang Y; Liu C; Chen H; Jiao X; Wang Y; Cao Y; Li J; Zhang X; Sun Y; Zhuo N; Dong F; Gao M; Wang F; Dong L; Gong J; Sun T; Zhu W; Zhang H; Shen L; Lu Z
    Signal Transduct Target Ther; 2024 Jun; 9(1):153. PubMed ID: 38937446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation.
    Du R; Xiao N; Han L; Guo K; Li K; Chen Z; Zhang H; Zhou Z; Huang Y; Zhao X; Bian H
    Sci Rep; 2024 Apr; 14(1):9167. PubMed ID: 38649770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1.
    Chang ZW; Jia YX; Zhang WJ; Song LJ; Gao M; Li MJ; Zhao RH; Li J; Zhong YL; Sun QZ; Qin YR
    J Exp Clin Cancer Res; 2018 Mar; 37(1):56. PubMed ID: 29530057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
    Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
    Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deoxypodophyllotoxin, a Lignan from
    Kwak AW; Lee MH; Yoon G; Cho SS; Choi JS; Chae JI; Shim JH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoliquiritigenin Suppressed Esophageal Squamous Carcinoma Growth by Blocking EGFR Activation and Inducing Cell Cycle Arrest.
    Ye L; Zhang J; Zhang Y; Gu B; Zhu H; Mao X
    Biomed Res Int; 2020; 2020():9259852. PubMed ID: 32190688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
    Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
    Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.
    Chen D; Hong R; Cao Y; Wu Q; Wang Y; Chen J; Li J; Zhang W; Zhan Q
    Carcinogenesis; 2023 Aug; 44(6):451-462. PubMed ID: 37279554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects and mechanisms of FBXO31 on Taxol chemoresistance in esophageal squamous cell carcinoma.
    Lv L; Wang SC; Mo JY; Huang KL; Xu ML; Liu J
    Biochem Biophys Res Commun; 2022 Jan; 586():129-136. PubMed ID: 34839191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma.
    Wang J; Zhang Z; Che Y; Yuan Z; Lu Z; Li Y; Wan J; Sun H; Chen Z; Pu J; He J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):469-481. PubMed ID: 29308536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy.
    Han L; Xiang X; Fu Y; Wei S; Zhang C; Li L; Liu Y; Lv H; Shan B; Zhao L
    Phytomedicine; 2024 Jun; 128():155539. PubMed ID: 38522311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.
    Meng RY; Jin H; Nguyen TV; Chai OH; Park BH; Kim SM
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
    Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
    J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
    Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
    Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.